ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

31378 results sorted by trial registration date.
  • TetraDERM for Scar Reduction

    The purpose of this study is to evaluate the extent of scar formation and to provide safety information for a new approach to scar formation after s surgical procedure. TetraDERM device uses the natural heat from the body to form an elastic hydrogel scaffold, the controls moisture within the wound bed whilst providing a cushioning effect physically to reduce the tension of the wound. TetraDERM creates an environment for new skin tissue to form that is similar to our bodies natural healing response. TetraDERM’s capability to control the hydration within the wound bed, to reduce wound tension and support healing work to reduce scar formation. Up to 8 subjects will be enrolled at one clinical site in Australia in cohort 1. There will be a total of 11 subject visits occurring over 12 months.

  • Handgrip echocardiography for the detection of early signs of heart dysfunction in women after preeclampsia

    Preeclampsia and hypertensive disorders of pregnancy are associated with a significant increase in the risk of developing early onset cardiovascular diseases, including heart failure. This project is investigating the ability for isometric handgrip echocardiography to detect early signs of diastolic dysfunction in the heart, prior to changes being observed by traditional resting echocardiography and clinical signs of heart failure. This may facilitate future studies into early intervention in this population.

  • A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of a Single Intravenous Infusion of TRP-8803 (Psilocin) in Healthy Adult Participants

    Psilocin (4-Hydroxy-N,N-dimethyltryptamine) is the active form of the prodrug psilocybin (3[2(dimethylamino) ethyl]-1H-indol-4-yl] dihydrogen phosphate). Psilocybin is a natural product produced by numerous species of Psilocybe mushrooms. In humans, psilocybin is not detectable in systemic circulation or in target organs after oral administration as the phosphate group of psilocybin (a tryptamine derivative) is rapidly enzymatically cleaved to the active pharmacologic moiety psilocin . Thus, studies administering psilocybin are by default results for psilocin due to the almost immediate conversion of psilocybin to the active form psilocin. Administration of TRP8803 IV over a controlled time has potential advantages over oral administration of psilocybin such as improved control over blood levels of psilocin, faster entry into the psychedelic state, better control over the duration of the psychedelic state, and increased safety due to rapid offset of effects and avoidance of peak blood levels (Cmax) associated with oral administration. From a clinical research perspective TRP-8803 provides a mechanism to explore both the depth and duration of the psychedelic experience and how these parameters affect clinical outcomes. Infusing TRP-8803 with a bolus over the first 20 minutes (loading dose) allows attainment of Cmax in a controlled protocol and subsequent infusions for a total of 7.5, 14, or 20.5 mg over 140 minutes allows for maintenance of the psychedelic experience at a therapeutic dose. IV administration allows for the physician to control and optimize the psilocin dose.

  • A trial to assess the safety and tolerability of EBC-1013 Gel in participants with venous leg ulcers.

    The purpose of this study is to assess the safety and tolerability (how well a treatment can be tolerated by a patient) of EBC-1013 Gel. This study will be conducted in patients with Venous Leg Ulcers, aged 18 years and above. This study will compare EBC-1013 Gel with placebo. A placebo is a medication with no active ingredients. It looks similar to the real thing, but it is not. Participants enrolled in this study will be placed into one of five different groups. Each group will receive a single treatment with one of five different dose levels of EBC-1013 Gel (0.1, 0.3, 0.6, 1.0 and 1.5 mg/g). One participant in each of the groups will receive placebo. The effects seen in participants receiving the study drug will be compared to the effects seen in participants who receive placebo. Each group will involve a minimum of 4 participants (1 placebo and 3 active). A maximum of 7 participants will be enrolled in each cohort (1 placebo, 6 active) if any safety signals are observed in that cohort.

  • Effects of calcium on gut hormone secretion in healthy participants

    The purpose of this trial is to investigate the acute dose-related effects of intraduodenal administration of calcium on gastrointestinal functions, associated with the regulation of appetite and energy intake, in healthy participants.

  • Love Your Brain: A Digital Platform for Preventing Stroke [Stage 2: Pilot]

    Stroke affects approximately 1 in 4 people in their lifetime, but is highly preventable through effective management of risk factors such as smoking, inadequate diet, high blood pressure and physical inactivity. Love Your Brain is a digital platform to improve the knowledge of Australians in stroke prevention, by helping people identify and manage their risk factors for stroke. We will determine the feasibility and acceptance of the implementation of the proposed intervention in a sample of attendees of Stroke Foundation StrokeSafe presentations and obtain data to inform the design of a fully powered randomised controlled trial.

  • Evaluating a prehospital model of care involving risk assessment, point-of-care troponin, and virtual emergency department to accelerate the provision of definitive care for chest pain

    Chest pain is the leading cause of Ambulance Victoria attendance and costs $337 million per year. Currently, all patients with chest pain are transported to hospital, but half will be discharged safely from Emergency Departments, at a cost of $135 million every year. We have developed a new Ambulance Victoria clinical practice guideline (CPG) for these low risk patients using risk assessment, point-of-care blood testing by paramedics, and Victorian Virtual Emergency Department consultation with referral for follow-up in the outpatient or general practice setting. We will now conduct a comprehensive evaluation of the new CPG via a randomised trial with safety, effectiveness, quality of care, process, and economic components. The outcomes span from the rapid reduction of ED overcrowding and ambulance ramping in the short term to the development of streamlined follow-up pathways and significant cost savings in the medium and long term. Through this innovative model, we will optimise patient outcomes and contribute to a more efficient and economically sustainable healthcare system for the benefit of all stakeholders.

  • Effect of an electric fan on sleep quality in hot overnight environments in young healthy adults

    Humans require sufficient sleep to maintain physical and mental health. Reductions in sleep quantity and quality are associated with reduced cognitive function and productivity and increased absenteeism, along with chronic diseases such as hypertension and cardiovascular disease, dementia, depression and anxiety. Laboratory studies have shown that hot temperatures result in worse sleep, with epidemiological data suggesting that hot overnight conditions are independently related to mortality. To date, nearly all solutions for combatting heat stress are pre-occupied with reducing air temperature – usually using air conditioning (AC). Currently, despite no supporting evidence, all major international public health agencies (including WHO) state that fans should be turned OFF above 32-35°C as they accelerate heat/dehydration risk. A series of recent publications from our research group has shown that fans can mitigate heat stress at temperatures as high as 42°C. However, how these findings translate to overnight fan use at these temperatures remains unknown. Thus, the purpose of this trial is to test the use of electric fans to improve sleep quantity and quality in ambient conditions of 35°C and 40% Relative Humidity.

  • Amnion cell therapy for ulcerative proctitis

    Apart from topical aminosalicylates and steroids, there is limited local treatment available for ulcerative proctitis, a incurable relapsing inflammatory condition of the bowel. This study aims to assess the safety of using locally injected stem cells derived from healthy placentas to treat ulcerative proctitis. Participants will receive a single injection of cells during routine colonoscopy and undergo assessment using routine colonoscopy, blood tests and stool tests. We hypothesise that these placental-derived stem cells will be safe and well-tolerated and that local injection is feasible.

  • Telehealth delivered motivational interviewing and cognitive behaviour therapy to support exercise-based rehabilitation for people with lower limb osteoarthritis: a pilot randomized control trial

    Identify the feasibility of MI-CBT via telehealth in supporting people with knee/hip osteoarthritis to uptake and adhere to a walking program based on rehabilitation. Hypothesis: Telehealth based on MI-CBT is feasible.

Tags:
  • Finding clinical trials